Macrophage migration inhibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis

Shock

Volumn 24, Issue 6, 2006, Pages 556-563

  Lin, Xinchun ^a   Sakuragi, Tohru ^a,b   Metz, Christine N ^a   Ojamaa, Kaie ^a   Skopicki, Hal A ^a   Wang, Fing ^a   Al Abed, Yousef ^a   Miller, Edmund J ^a,c  

^a Institute for Medical Research at North Shore LIJ Health System ^*  (United States)

^b SAGA UNIVERSITY   (Japan)

^c Institute for Medical Research at North Shore LIJ   (United States)

Author keywords

Cardiac dysfunction; Lung; Macrophage migration inhibitory factor; Sepsis

Indexed keywords

CHEMOKINE; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; EXPERIMENTAL SEPSIS; HEART DISEASE; HUMAN; HUMAN CELL; LUNG ALVEOLUS; LUNG CIRCULATION; MIXED INFECTION; MOUSE; NEWBORN; NONHUMAN; RAT; RESPIRATORY FAILURE; SEPSIS; SHOCK;

EID: 33646804549     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000183238.70374.a8     Document Type: Article

References (46)

1. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984.
2. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336:912-918, 1997.
3. Zilberberg MD, Epstein SK: Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 157:1159-1164, 1998.
4. Lu Y, Song Z, Zhou X, Huang S, Zhu D, Yang CBX, Sun B, Spragg R: A 12-month clinical survey of incidence and outcome of acute respiratory distress syndrome in Shanghai intensive care units. Intensive Cure Med 30:2197-2203, 2004.
5. Vincent JL, Gris P, Coffernils M, Leon M, Pinsky M, Reuse C, Kahn RJ: Myocardial depression characterizes the fatal course of septic shock. Surgery 111:660-667, 1992.
6. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W: A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76:1539-1553, 1985.
7. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351:929-933, 1998.
8. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115-1124, 1997.
9. Cobb JP: Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg Infect 2:93-100; discussion 100-101, 2001.
10. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-346, 1999.
11. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R: MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467-1476, 2003.
12. Calandra T, Bucala R: Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 47:39-51, 1995.
13. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN, Bruce LJ, Bucala R: Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3:320-323, 1997.
14. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71, 1995.
15. Garner LB, Willis MS, Carlson DL, DiMaio JM, White MD, White DJ, Adams GAT, Horton JW, Giroir BP: Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 285:H2500-H2509, 2003.
16. Chagnon F, Metz CN, Bucala R, Lesur O: Endotoxin-induced myocardial dysfunction. Effects of macrophage migration inhibitory factor (MIF) neutralization. Circ Res 96:1095-1102, 2005.
17. Bozza M, Gomes RN, Japiassu AM, Soares MCFN, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22:309-313, 2004.
18. Beishuizen A, Thijs LG, Haanen C, Vermes I: Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86:2811-2816, 2001.
19. Pittet JF, Mackersie RC, Martin TR, Matthay MA: Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 155:1187-1205, 1997.
20. Prescott SM, McIntyre TM, Zimmerman G: Two of the usual suspects, platelet-activating factor and its receptor, implicated in acute lung injury. J Clin Invest 104:1019-1020, 1999.
21. Miller EJ, Cohen AB, Matthay MA: Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis. Crit Care Med 24:1448-1454, 1996.
22. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Metz C, Miller EJ, Tracey KJ, Ulloa L: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216-1221, 2004.
23. Cui X, Wu R, Zhou M, Simms HH, Wang P: Differential expression of cytochrome P450 isoforms in the lungs of septic animals. Crit Care Med 32:1186-1191, 2004.
24. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33:14144-14155, 1994.
25. Dios A, Mitchell RA, Aljabari B, Lubetsky J, O'Connor K, Liao H, Senter PD, Manogue KR, Lolis E, Metz C, et al.: Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 45:2410-2416, 2002.
26. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
27. Davidson MC, Qu X, Chen D, Skopicki HA: Transcription factor control of myogenic differentiation in a myogenic model cell line. J Am Coll Cardiol 35:215A, 2000.
28. Gilbert C, Rollet-Labelle E, Caon AC, Naccache PH: Immunoblotting and sequential lysis protocols for the analysis of tyrosine phosphorylation- dependent signaling. J Immunol Methods 271:185-201, 2002.
29. Kenessey A, Ojamaa K: Ligand-mediated decrease of thyroid hormone receptor-α1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability. Am J Physiol Heart Circ Physiol 288:H813-H821, 2005.
30. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273:2161-2168, 1998.
31. 2 in rat cardiac myocytes. Am J Physiol Cell Physiol 281:C1542-C1550, 2001.
32. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, et al.: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408:211-216, 2000.
33. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113:227-242, 1990.
34. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russell JA: A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 104:230-235, 1993.
35. Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, Schein R, Summer W, Wright P, Walley KR: Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 28:3405-3411, 2000.
36. Monchi M, Bellenfant F, Cariou A, Joly LM, Thebert D, Laurent I, Dhainaut JF, Brunet F: Early predictive factors of survival in the acute respiratory distress syndrome. A multivariate analysis. Am J Respir Crit Care Med 158:1076-1081, 1998.
37. Yin K, Wilmanski J, Wang C, Qiu G, Tahamont M: Lung compartmentalization of inflammatory cells in sepsis. Inflammation 24:547-557, 2000.
38. Lin X, Yang H, Sakuragi T, Hu M, Mantell LL, Hayashi S, Al-Abed Y, Tracey KJ, Ulloa L, Miller EJ: α-Chemokine receptor blockade reduces high mobility group box 1 (HMGB1) protein-induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol 289:L583-590, 2005.
39. Tsujimoto H, Ono S, Majima T, Kawarabayashi N, Takayama E, Kinoshita M, Seki S, Hiraide H, Moldawer LL, Mochizuki H: Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 23:39-44, 2005.
40. Mercer-Jones MA, Hadjiminas DJ, Heinzelmann M, Peyton J, Cook M, Cheadle WG: Continuous antibiotic treatment for experimental abdominal sepsis: effects on organ inflammatory cytokine expression and neutrophil sequestration. Br J Surg 85:385-389, 1998.
41. Martin TR, Pistorese BP, Chi EY, Goodman RB, Matthay MA: Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin invest 84:1609-1619, 1989.
42. Berton G, Yan SR, Fumagalli L, Lowell CA: Neutrophil activation by adhesion: mechanisms and pathophysiological implications. Int J Clin Lab Res 26:160-177, 1996.
43. 2 production in adherent human neutrophils. J Immunol 152:290-300, 1994.
44. Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR, Weiner-Kronish JP, Sticherling M, Christophers E, Matthay MA: Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 146:427-432, 1992.
45. Zheng M, Hou R, Xiao RP: Acidosis-induced p38 MAPK activation and its implication in regulation of cardiac contractility. Acta Pharmacol Sin 25:1299-1305, 2004.
46. Loken L, Brahmbhatt S, Sharma AC: Effect of p38-MAPK inhibition on sepsis-induced myocardial dysfunction. Shock 23:82, 2005.